SelectScience
Join Free
NewsLife Sciences

Fujirebio launches the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood tests

Fujirebio

The new biomarker tests will allow further study of the clinical utility of NfL in diverse disease conditions

27 Mar 2023
Jessica Calvey
Product and Reviews Admin Assistant

Product news

H.U. Group Holdings Inc., and its wholly owned subsidiary Fujirebio, have announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems. These chemiluminescent enzyme immunoassay (CLEIA) assays allow for the quantitative measurement of neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes*.

The new biomarker tests will allow researchers and clinical research professionals to further study the clinical utility of NfL in diverse disease conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease, as well as in acute situations such as traumatic brain injury. NfL is considered a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies.

Laboratory professionals can select their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardized immunoassay system family is widely available and used in routine labs active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform meets the necessary throughput, quality, and regulatory requirements to support possible future routine use of NfL in addition to the existing portfolio.

“In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” said Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative disease field as quickly as possible.”

*The two assays are available for research use only.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Related products

Request Quote for All Products

Lumipulse® G NfL Blood (RUO)

Fujirebio

Immunoassay to be used with the automated LUMIPULSE G System for the quantitative measurement of neurofilament light (NfL) in human plasma and serum. 

(0)

Links

FujirebioCompany website

Tags

BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :AutomationAutomation in laboratories and manufacturing processes enhances efficiency, precision, and scalability by reducing the need for manual intervention. It plays a critical role in improving productivity, minimizing human error, and accelerating workflows in fields like diagnostics, drug development, and industrial testing. Automation technologies include robotic systems, automated liquid handlers, and process control systems that streamline complex tasks and ensure consistent, reproducible results. Explore our peer-reviewed product directory to discover the best automation solutions, compare options, read user reviews, and get prices directly from manufacturers.Assay DevelopmentThe process of proving an assay to be sensitive with respect to the target is known as assay development. The assay should be able to characterize novel compounds and measure the potency of these compounds against a validated biological target.NeurodegenerationNeurodegeneration refers to the progressive deterioration of the structure and function of the nervous system, often seen in diseases like Alzheimer's and Parkinson's. Research focuses on early detection and potential therapies. Explore neurodegeneration research tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.

Related articles

Fujirebio launches the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood tests